Elranatamab-bcmm
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Edzel Lorraine Co, DMD, MD[2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Elranatamab-bcmm is {{{aOrAn}}} {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. Common adverse reactions include {{{adverseReactions}}}.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Elranatamab-bcmm FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Elranatamab-bcmm FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Contraindications
There is limited information regarding Elranatamab-bcmm Contraindications in the drug label.
Warnings
There is limited information regarding Elranatamab-bcmm Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Elranatamab-bcmm Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Elranatamab-bcmm Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Elranatamab-bcmm Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Elranatamab-bcmm in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Elranatamab-bcmm in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Elranatamab-bcmm during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Elranatamab-bcmm in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Elranatamab-bcmm in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Elranatamab-bcmm in geriatric settings.
Gender
There is no FDA guidance on the use of Elranatamab-bcmm with respect to specific gender populations.
Race
There is no FDA guidance on the use of Elranatamab-bcmm with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Elranatamab-bcmm in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Elranatamab-bcmm in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Elranatamab-bcmm in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Elranatamab-bcmm in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Elranatamab-bcmm Administration in the drug label.
Monitoring
There is limited information regarding Elranatamab-bcmm Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Elranatamab-bcmm and IV administrations.
Overdosage
There is limited information regarding Elranatamab-bcmm overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Elranatamab-bcmm Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Elranatamab-bcmm Mechanism of Action in the drug label.
Structure
There is limited information regarding Elranatamab-bcmm Structure in the drug label.
Pharmacodynamics
There is limited information regarding Elranatamab-bcmm Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Elranatamab-bcmm Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Elranatamab-bcmm Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Elranatamab-bcmm Clinical Studies in the drug label.
How Supplied
There is limited information regarding Elranatamab-bcmm How Supplied in the drug label.
Storage
There is limited information regarding Elranatamab-bcmm Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Elranatamab-bcmm |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Elranatamab-bcmm |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Elranatamab-bcmm Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Elranatamab-bcmm interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Elranatamab-bcmm Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Elranatamab-bcmm Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.